Literature DB >> 15882431

The pathophysiology of acute graft-versus-host disease.

M Jaksch1, J Mattsson.   

Abstract

Despite improvements in allogeneic stem cell transplantation, acute graft-versus-host disease (GVHD) remains a significant problem after transplantation, and it is still a major cause of post-transplant mortality. Disease progression is characterized by the differentiation of alloreactive T cells to effector cells leading to tissue damage, recruitment of additional inflammatory cell populations and further cytokine dysregulation. To make the complex process of acute GVHD more explicit, the pathophysiology of acute GVHD is often divided into three different phases. This review summarizes the mechanisms involved in the three phases of acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882431     DOI: 10.1111/j.1365-3083.2005.01595.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation.

Authors:  Courtney M Lappas; Po-Ching Liu; Joel Linden; Elizabeth M Kang; Harry L Malech
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

2.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

Review 3.  Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes.

Authors:  Rihab Gam; Pranali Shah; Rachel E Crossland; Jean Norden; Anne M Dickinson; Ralf Dressel
Journal:  Front Immunol       Date:  2017-04-03       Impact factor: 7.561

4.  Lithothamnion muelleri controls inflammatory responses, target organ injury and lethality associated with graft-versus-host disease in mice.

Authors:  Barbara M Rezende; Priscila T T Bernardes; Carolina B Resende; Rosa M E Arantes; Danielle G Souza; Fernão C Braga; Marina G M Castor; Mauro M Teixeira; Vanessa Pinho
Journal:  Mar Drugs       Date:  2013-07-18       Impact factor: 5.118

5.  Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).

Authors:  Nikolas von Bubnoff; Gabriele Ihorst; Olga Grishina; Nadine Röthling; Hartmut Bertz; Justus Duyster; Jürgen Finke; Robert Zeiser
Journal:  BMC Cancer       Date:  2018-11-19       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.